ALK proposes to acquire the largest allergy vaccine company in the Netherlands
Copenhagen-based ALK-Abelló and Dutch-based Fornix BioSciences (“Fornix“) have today entered into an agreement to the effect that ALK proposes to acquire the Dutch activities of Fornix’ Allergy Division, Artu Biologicals (“Artu“), for a cash consideration of EUR 19.6 million (DKK 146 million) on a debt and cash free basis.
The proposal to acquire Artu is part of ALK’s strategy of expanding its global presence and of contributing to the consolidation of the allergy vaccine industry caused by increased regulatory requirements to products.
The proposal to acquire Artu is part of ALK’s strategy of expanding its global presence and of contributing to the consolidation of the allergy vaccine industry caused by increased regulatory requirements to products.
